296 related articles for article (PubMed ID: 25854145)
1. Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15.
Wang X; D'Arcy P; Caulfield TR; Paulus A; Chitta K; Mohanty C; Gullbo J; Chanan-Khan A; Linder S
Chem Biol Drug Des; 2015 Nov; 86(5):1036-48. PubMed ID: 25854145
[TBL] [Abstract][Full Text] [Related]
2. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
Wang X; Mazurkiewicz M; Hillert EK; Olofsson MH; Pierrou S; Hillertz P; Gullbo J; Selvaraju K; Paulus A; Akhtar S; Bossler F; Khan AC; Linder S; D'Arcy P
Sci Rep; 2016 Jun; 6():26979. PubMed ID: 27264969
[TBL] [Abstract][Full Text] [Related]
3. Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15.
Mofers A; Perego P; Selvaraju K; Gatti L; Gullbo J; Linder S; D'Arcy P
PLoS One; 2019; 14(10):e0223807. PubMed ID: 31639138
[TBL] [Abstract][Full Text] [Related]
4. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells.
Chitta K; Paulus A; Akhtar S; Blake MK; Caulfield TR; Novak AJ; Ansell SM; Advani P; Ailawadhi S; Sher T; Linder S; Chanan-Khan A
Br J Haematol; 2015 May; 169(3):377-90. PubMed ID: 25691154
[TBL] [Abstract][Full Text] [Related]
5. Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress.
Brnjic S; Mazurkiewicz M; Fryknäs M; Sun C; Zhang X; Larsson R; D'Arcy P; Linder S
Antioxid Redox Signal; 2014 Dec; 21(17):2271-85. PubMed ID: 24011031
[TBL] [Abstract][Full Text] [Related]
6. Proteasome deubiquitinases as novel targets for cancer therapy.
D'Arcy P; Linder S
Int J Biochem Cell Biol; 2012 Nov; 44(11):1729-38. PubMed ID: 22819849
[TBL] [Abstract][Full Text] [Related]
7. Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth.
Cao MN; Zhou YB; Gao AH; Cao JY; Gao LX; Sheng L; Xu L; Su MB; Cao XC; Han MM; Wang MK; Li J
Biochim Biophys Acta; 2014 Jun; 1840(6):2004-13. PubMed ID: 24534329
[TBL] [Abstract][Full Text] [Related]
8. The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells.
Schmidt M; Altdörfer V; Schnitte S; Fuchs AR; Kropp KN; Maurer S; Müller MR; Salih HR; Rittig SM; Grünebach F; Dörfel D
Neoplasia; 2019 Jul; 21(7):653-664. PubMed ID: 31132676
[TBL] [Abstract][Full Text] [Related]
9. The 19S Deubiquitinase inhibitor b-AP15 is enriched in cells and elicits rapid commitment to cell death.
Wang X; Stafford W; Mazurkiewicz M; Fryknäs M; Brjnic S; Zhang X; Gullbo J; Larsson R; Arnér ES; D'Arcy P; Linder S
Mol Pharmacol; 2014 Jun; 85(6):932-45. PubMed ID: 24714215
[TBL] [Abstract][Full Text] [Related]
10. Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase.
Chen X; Wu J; Yang Q; Zhang X; Zhang P; Liao S; He Z; Wang X; Zhao C; Liu J
Biometals; 2018 Feb; 31(1):29-43. PubMed ID: 29098502
[TBL] [Abstract][Full Text] [Related]
11. Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma.
Jiang L; Sun Y; Wang J; He Q; Chen X; Lan X; Chen J; Dou QP; Shi X; Liu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):453. PubMed ID: 31694672
[TBL] [Abstract][Full Text] [Related]
12. Acute lymphoblastic leukemia cells are sensitive to disturbances in protein homeostasis induced by proteasome deubiquitinase inhibition.
Mazurkiewicz M; Hillert EK; Wang X; Pellegrini P; Olofsson MH; Selvaraju K; D'Arcy P; Linder S
Oncotarget; 2017 Mar; 8(13):21115-21127. PubMed ID: 28423502
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?
Selvaraju K; Mazurkiewicz M; Wang X; Gullbo J; Linder S; D'Arcy P
Drug Resist Updat; 2015; 21-22():20-9. PubMed ID: 26183292
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.
Rowinsky EK; Paner A; Berdeja JG; Paba-Prada C; Venugopal P; Porkka K; Gullbo J; Linder S; Loskog A; Richardson PG; Landgren O
Invest New Drugs; 2020 Oct; 38(5):1448-1453. PubMed ID: 32125598
[TBL] [Abstract][Full Text] [Related]
15. Deubiquitinase inhibition as a cancer therapeutic strategy.
D'Arcy P; Wang X; Linder S
Pharmacol Ther; 2015 Mar; 147():32-54. PubMed ID: 25444757
[TBL] [Abstract][Full Text] [Related]
16. Induction of ER Stress in Acute Lymphoblastic Leukemia Cells by the Deubiquitinase Inhibitor VLX1570.
Pellegrini P; Selvaraju K; Faustini E; Mofers A; Zhang X; Ternerot J; Schubert A; Linder S; D Arcy P
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32635430
[TBL] [Abstract][Full Text] [Related]
17. Deubiquitinases (DUBs) and DUB inhibitors: a patent review.
Farshi P; Deshmukh RR; Nwankwo JO; Arkwright RT; Cvek B; Liu J; Dou QP
Expert Opin Ther Pat; 2015; 25(10):1191-1208. PubMed ID: 26077642
[TBL] [Abstract][Full Text] [Related]
18. A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy.
Zhao C; Chen X; Zang D; Lan X; Liao S; Yang C; Zhang P; Wu J; Li X; Liu N; Liao Y; Huang H; Shi X; Jiang L; Liu X; He Z; Dou QP; Wang X; Liu J
Oncogene; 2016 Nov; 35(45):5916-5927. PubMed ID: 27086925
[TBL] [Abstract][Full Text] [Related]
19. Identification of 4-arylidene curcumin analogues as novel proteasome inhibitors for potential anticancer agents targeting 19S regulatory particle associated deubiquitinase.
Yue X; Zuo Y; Ke H; Luo J; Lou L; Qin W; Wang Y; Liu Z; Chen D; Sun H; Zheng W; Zhu C; Wang R; Wen G; Du J; Zhou B; Bu X
Biochem Pharmacol; 2017 Aug; 137():29-50. PubMed ID: 28476333
[TBL] [Abstract][Full Text] [Related]
20. Deubiquitinase inhibition of 19S regulatory particles by 4-arylidene curcumin analog AC17 causes NF-κB inhibition and p53 reactivation in human lung cancer cells.
Zhou B; Zuo Y; Li B; Wang H; Liu H; Wang X; Qiu X; Hu Y; Wen S; Du J; Bu X
Mol Cancer Ther; 2013 Aug; 12(8):1381-92. PubMed ID: 23696216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]